CN116421482A - Composition containing tricholoma matsutake extract with anti-aging effect and application thereof - Google Patents
Composition containing tricholoma matsutake extract with anti-aging effect and application thereof Download PDFInfo
- Publication number
- CN116421482A CN116421482A CN202310432643.2A CN202310432643A CN116421482A CN 116421482 A CN116421482 A CN 116421482A CN 202310432643 A CN202310432643 A CN 202310432643A CN 116421482 A CN116421482 A CN 116421482A
- Authority
- CN
- China
- Prior art keywords
- skin
- tricholoma matsutake
- composition
- extract
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 241000121220 Tricholoma matsutake Species 0.000 title claims abstract description 77
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 31
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 claims abstract description 34
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 34
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 claims abstract description 34
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 claims abstract description 34
- 229940117895 bakuchiol Drugs 0.000 claims abstract description 34
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 34
- 206010051246 Photodermatosis Diseases 0.000 claims abstract description 19
- 230000008845 photoaging Effects 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- 230000002255 enzymatic effect Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 229940121672 Glycosylation inhibitor Drugs 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 45
- 230000006378 damage Effects 0.000 abstract description 15
- 230000037303 wrinkles Effects 0.000 abstract description 15
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract description 10
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract description 10
- 206010015150 Erythema Diseases 0.000 abstract description 8
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 8
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 8
- 231100000321 erythema Toxicity 0.000 abstract description 8
- 238000007254 oxidation reaction Methods 0.000 abstract description 8
- 230000036542 oxidative stress Effects 0.000 abstract description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 6
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 230000008591 skin barrier function Effects 0.000 abstract description 5
- 239000000419 plant extract Substances 0.000 abstract description 4
- 206010013786 Dry skin Diseases 0.000 abstract description 3
- 230000037336 dry skin Effects 0.000 abstract description 3
- 230000008832 photodamage Effects 0.000 abstract description 3
- 206010040867 Skin hypertrophy Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 238000006206 glycosylation reaction Methods 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 9
- 230000008439 repair process Effects 0.000 description 9
- 230000032683 aging Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000000469 ethanolic extract Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 229930003427 Vitamin E Natural products 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 229940046009 vitamin E Drugs 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VSMOENVRRABVKN-UHFFFAOYSA-N oct-1-en-3-ol Chemical compound CCCCCC(O)C=C VSMOENVRRABVKN-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 230000002087 whitening effect Effects 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- UHGGERUQGSJHKR-VCDGYCQFSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;octadecanoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCCCCCCCC(O)=O UHGGERUQGSJHKR-VCDGYCQFSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000226566 Psoralea corylifolia Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 108010058393 monophenolase Proteins 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition containing tricholoma matsutake extract with anti-aging effect and application thereof. The invention provides a composition with anti-aging effect, which comprises tricholoma matsutake extract, ergothioneine and bakuchiol, wherein the composition has good repairing effect on UV-induced skin photoaging damage; the components are compounded according to different proportions, the drug effect is obviously superior to the simple superposition of the single use of each component or the combined use of the two components, the synergistic effect is obvious, the damage states of dry skin, erythema, rough wrinkles, skin thickening and the like can be avoided, the levels of oxidative stress and inflammatory factors IL-1 beta, IL-6, COX-2 and TNF-alpha can be obviously reduced, the skin photodamage is avoided, the skin oxidization is effectively improved, the skin barrier function is repaired, and the skin is protected. The composition provided by the invention is a natural plant extract, has moderate material cost and preparation cost, is simple to prepare, has low toxic and side effects, and is easy to obtain.
Description
Technical Field
The invention belongs to the technical field of cosmetics. More particularly, relates to a composition containing tricholoma matsutake extract with anti-aging effect and application thereof.
Background
The skin is the largest organ of the human body, and the most important function is the barrier function, namely, the damage to the skin caused by external stimulus is prevented, and meanwhile, the water loss in the skin is prevented. With natural aging, progressive mitochondrial dysfunction occurs during aging, which increases ROS (reactive oxygen species) production, which can further lead to worsening mitochondrial function and overall cell damage. Under normal conditions, free radicals in skin cells are subjected to corresponding control mechanisms, so that the free radicals are maintained within a certain threshold range, and dynamic balance is maintained. A certain amount of free radicals play an important role in energy transfer, inflammation elimination, necrotic cell removal and other aspects, however, when an organism is in a unfavorable environment or cells are in an anoxic state for a long time, or strong light or high-temperature environment and the like, excessive ROS cannot be timely removed, the free radicals accumulated in the organism cause various harm to the cells, the excessive active oxygen free radicals easily initiate peroxidation, damage the biomembrane structure and directly threaten the internal environment and steady state in the cells, and meanwhile, the living radical can oxidize macromolecular proteins to cause cross-linking accumulation of the proteins, and even cause the functional proteins to lose the original bioactivity.
In addition, excessive DPPH active oxygen free radicals easily damage mitochondrial DNA, so that mitochondrial genetic information cannot be expressed normally, the operation of an energy conversion enzyme action system is seriously influenced, and the DNA in the nucleus can be accumulated by the free radicals, so that the gene sequence is changed, and the gene mutation is induced. Oxidative stress induced by excessive ROS in cells causes abnormal cell functions, and causes different degrees of injury to physiological functions of organisms, thereby triggering human aging and related diseases.
Among them, in the natural aging process, most commonly skin injury caused by ultraviolet radiation (UVB), UVB may damage the dermis layer, collagen is damaged, elastane is problematic, skin becomes loose, wrinkles appear, when photoaging is serious, the skin wrinkles are hard to recover through skin care products, expression lines are accumulated and accumulated day by day, so that the skin presents an old state, and expression lines are an important factor for the skin to present an aging state.
The main components of most of the existing anti-photoaging products are non-natural components and auxiliary materials which are mixed for use. The non-natural components adopted by the cosmetic composition are mainly retinol, however, people using the retinol for the first time can experience desquamation, which is one of the most common side effects of the retinol, and the adverse effects can disappear by themselves after the skin is adapted to the product; another common adverse effect is dry skin and itching, which, although can be addressed by the use of moisturizing liquids or other moisturizing ingredients, can have some effect on the skin. In the prior art, the anti-aging product obtained by compounding the natural plant extract has the characteristics of green and safety and low side effect, and the anti-aging product mainly has the main effect of supplementing skin vitamins although the influence of non-natural components on the skin can be avoided. Therefore, there is a need to develop and select more effective natural plant extracts that are simple to prepare for use in combination, and to prepare products that are effective in retarding skin oxidation and combating the skin problems of aging caused by UV irradiation.
Disclosure of Invention
In order to overcome the problems, the invention provides a composition containing tricholoma matsutake extract with anti-aging effect and application thereof, and the composition can effectively relieve skin oxidization, anti-aging skin problems, repair the barrier function of skin and restore the skin to a healthy state, and aims to provide more efficient anti-aging products.
The invention aims to provide a composition with anti-aging effect.
Another object of the present invention is to provide the use of a composition comprising an extract of Tricholoma matsutake.
The above object of the present invention is achieved by the following technical scheme:
the invention provides a composition with anti-aging effect, which comprises the following components: pine mushroom extract, ergothioneine and bakuchiol. The research of the invention shows that the composition obtained by compounding the tricholoma matsutake extract, the bakuchiol and the ergothioneine has the effect obviously superior to the simple superposition of the single use of each component or the matched use of the two components, has obvious synergistic effect, can obviously inhibit non-enzymatic glycosylation and has good anti-aging effect; has good repairing effect on UV-induced skin photoaging injury, can avoid injury states such as skin dryness, erythema, rough wrinkles, epidermis thickening and the like, can obviously reduce the level of oxidative stress and inflammatory factors IL-1 beta, IL-6, COX-2 and TNF-alpha, lighten skin inflammation, avoid causing skin photoinjury, effectively improve skin oxidation, repair skin barrier function and protect skin.
Further, the mass ratio of the tricholoma matsutake extract to the bakuchiol to the ergothioneine is as follows: (1-10): (0.1-1): (0.01-0.05).
Preferably, the mass ratio of the tricholoma matsutake extract to the bakuchiol to the ergothioneine is as follows: (5-10): (0.5-1): (0.01-0.03).
Preferably, the mass ratio of the tricholoma matsutake extract to the bakuchiol to the ergothioneine is as follows: (5-7.5): (0.5-0.75): (0.01-0.02).
More preferably, the mass ratio of the tricholoma matsutake extract, the bakuchiol and the ergothioneine is as follows: 5:0.5:0.01.
The composition with the anti-aging effect provided by the invention is prepared from natural extracts: the composition comprises the components of tricholoma matsutake extract, ergothioneine and bakuchiol, wherein the tricholoma matsutake extract can remove DPPH free radicals at the tail end of mitochondria, the ergothioneine has the effects of removing free radicals, detoxication, maintaining the biosynthesis efficacy of DNA, and the bakuchiol has an antioxidation effect. The composition provided by the invention achieves the anti-aging effect by inhibiting non-enzymatic glycosylation reaction, scavenging free radicals, strengthening skin barrier and the like, and the components are synergistic and complement each other to repair the skin barrier function.
The Tricholoma matsutake extract is prepared from Tricholoma Matsutake (TMP) which is a fungus with homology of medicine and food, and contains abundant saccharide, amino acid and polypeptide, volatile substances, vitamins, minerals, and lipid substances. The tricholoma matsutake has the pharmacological effects of resisting radiation, regulating immunity, whitening skin, resisting photoaging, resisting diabetes, resisting hypertension, regulating intestines and stomach, resisting oxidation, resisting cancer, resisting tumor and the like, and has high edible and medicinal values. In recent years, various researches on the use of tricholoma matsutake or tricholoma matsutake extract in the research and development of cosmetics prove that the active ingredients in the tricholoma matsutake extract have remarkable effects on the aspects of skin aging resistance, oxidation resistance, whitening and wrinkle resistance, and have wide market prospect. Therefore, the tricholoma matsutake extract is applied to cosmetics, and accords with the development trend of safety, nature and green of modern cosmetics.
The preparation method of the tricholoma matsutake extract adopted by the invention comprises the following steps: adding 75-85% ethanol solution into dried Tricholoma matsutake according to a feed liquid ratio of 1 (5-15), heating in water bath at 70-80deg.C for 1-3 hr, extracting for 2-3 times, filtering, concentrating, and diluting to obtain Tricholoma matsutake extract.
Further preferably, the preparation method of the tricholoma matsutake extract comprises the following steps: adding 75% ethanol solution into dried Tricholoma matsutake at a feed liquid ratio of 1:10, heating in water bath at 80deg.C for 2 hr, extracting for 2 times, filtering, concentrating, and diluting.
Ergothioneine (EGT) is a natural antioxidant which is safe and nontoxic, mainly derived from plants such as mushrooms, broccoli, brussels sprouts and the like, and has various physiological functions of scavenging free radicals, detoxication, maintaining DNA biosynthesis, normal growth of cells, cell immunity and the like; can protect cells in human body, and is an important active substance in the body. Natural antioxidants have become a hotspot in research.
Preferably, the ergothioneine used in the present invention can be prepared by methods conventional in the art, and can also be used directly by purchasing the product, and the purity of the ergothioneine is not less than 98%.
The bakuchiol is derived from mature fruits of Psoralea corylifolia of Leguminosae, has effects of controlling oil, resisting acne, inhibiting bacteria, and relieving inflammation, and can be used for treating skin darkness and pigmentation after inflammation, and its whitening principle is to inhibit activity of aminoplast monophenolase and diphenolase, and has certain whitening effect. In addition, the bakuchiol has good antioxidation and anti-aging effects, is a fat-soluble antioxidant which is stronger than vitamin E, can inhibit lipid peroxidation induced by free radicals, can prevent ultraviolet rays from damaging skin, and can delay apoptosis of cells.
Preferably, the bakuchiol adopted by the invention can be prepared by a conventional method in the field, and can also be directly used by purchasing products, and the purity of the bakuchiol is not lower than 98 percent.
The invention provides application of the composition in preparation of anti-aging and anti-photoaging products.
The invention provides the use of the above composition in the preparation of a non-enzymatic glycosylation inhibitor.
The invention also provides an anti-aging and anti-photoaging product, which comprises the composition and auxiliary materials.
In particular, the research of the invention shows that the composition has good effect on anti-aging and anti-photoaging, in principle, the effect is better when the composition is used in more amount, but the use of other auxiliary materials, the balance effect and the cost are needed to be considered for preparing different products, the effect and the suitability of the raw materials are controlled, the invention is not limited by the amount of the composition contained in the product, but the product prepared by the composition can play a corresponding role under the premise of not influencing the effect of the composition.
Preferably, the auxiliary materials comprise at least one of moisturizer, antioxidant, emollient and preservative.
Preferably, the product is a skin care product or cosmetic product; more preferably, the skin care product is skin lotion, emulsion, cream, facial mask or essence, etc.
The invention has the following beneficial effects:
the invention provides a composition with anti-aging effect, which comprises the following components: pine mushroom extract, ergothioneine and bakuchiol. The research of the invention shows that the effect of compounding the tricholoma matsutake extract, the bakuchiol and the ergothioneine is obviously superior to the simple superposition of the single use of each component or the combination of the two components, has obvious synergistic effect, can obviously inhibit non-enzymatic glycosylation and has good anti-aging effect. The composition provided by the invention has good repairing effect on UV-induced skin photoaging damage, can avoid the occurrence of damage states such as dry skin, erythema, rough wrinkles, skin thickening and the like, can obviously reduce the level of oxidative stress and inflammatory factors such as IL-1 beta, IL-6, COX-2 and TNF-alpha, lightens skin inflammation, avoids causing skin photoaging, effectively improves skin oxidation, repairs skin barrier function and protects skin. Has synergistic effect.
The composition provided by the invention is a natural plant extract, has moderate material cost and preparation cost, is simple to prepare, has low toxic and side effects, is easy to obtain and low in price, and provides more efficient anti-aging products for the field of cosmetics.
Drawings
FIG. 1 is a graph of the results of photo-aging skin repair of mice from different compositions ((a) for photo-aging of the back of mice and repair in the dosing group, (b) for quantification of the pasi of the photo-aging of the back of mice, (C) for HE staining of the back skin of mice, 20X magnification scan (D) for quantification of the average thickness pasi of the tissue epidermis of mice; C blank, MC model, D example 1 composition, F example 3 composition, Y case 6 composition, G case 1 composition).
Detailed Description
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
Reagents and materials used in the following examples are commercially available unless otherwise specified.
The dried matsutake, bakuchiol and ergothioneine adopted in the following examples are all commercially available, and are experimental mice: KM mice (6-8 weeks of week old) were supplied by the carrot-Carlott Bio Inc.
Example 1 preparation of the composition
Pine mushroom extract: 200g of dried tricholoma matsutake is taken, 80% ethanol solution is added according to a feed liquid ratio of 1:10, water bath heating and extraction are carried out for 3h at 85 ℃ for 2-3 times, and then the tricholoma matsutake ethanol extract is obtained through filtration, concentration and dilution.
Bakuchiol: purchased from green biology ltd, 98% purity.
Ergothioneine: purchased from microphone company, 98% purity.
The composition provided by the embodiment is obtained by mixing three components according to a mass ratio of 5:0.5:0.01 after the tricholoma matsutake extract, the bakuchiol and the ergothioneine are respectively obtained according to the steps, and specifically, 5g tricholoma matsutake extract, 0.5g bakuchiol and 0.01g ergothioneine are adopted.
Example 2 preparation of the composition
Pine mushroom extract: 200g of dried tricholoma matsutake is taken, 80% ethanol solution is added according to a feed liquid ratio of 1:10, water bath heating and extraction are carried out for 3h at 85 ℃ for 2-3 times, and then the tricholoma matsutake ethanol extract is obtained through filtration, concentration and dilution.
Bakuchiol: purchased from green biology ltd, 98% purity.
Ergothioneine: purchased from microphone company, 98% purity.
The composition provided by the embodiment is obtained by mixing three components according to the mass ratio of 7.5:0.75:0.02 after the tricholoma matsutake extract, the bakuchiol and the ergothioneine are respectively obtained according to the steps, and specifically, 7.5g tricholoma matsutake extract, 0.75g bakuchiol and 0.02g ergothioneine are adopted.
Example 3 preparation of the composition
Pine mushroom extract: 200g of dried tricholoma matsutake is taken, 80% ethanol solution is added according to a feed liquid ratio of 1:10, water bath heating and extraction are carried out for 3h at 85 ℃ for 2-3 times, and then the tricholoma matsutake ethanol extract is obtained through filtration, concentration and dilution.
Bakuchiol: purchased from green biology ltd, 98% purity.
Ergothioneine: purchased from microphone company, 98% purity.
The composition provided by the embodiment is obtained by mixing three components according to a mass ratio of 10:1:0.03 after the tricholoma matsutake extract, the bakuchiol and the ergothioneine are respectively obtained according to the steps, and specifically, 10g tricholoma matsutake extract, 1.0g bakuchiol and 0.03g ergothioneine are adopted.
EXAMPLE 4 preparation of different component compositions
The invention simultaneously researches and prepares a plurality of compositions with different components and contents for subsequent detection research, the specific components and the contents thereof are shown in the following table 1, the preparation method of the tricholoma matsutake extract is the same as that of example 1, and the bakuchiol is purchased from green biology company and has the purity of 98%; ergothioneine was purchased from microphone company at 98% purity.
TABLE 1 composition content of the different Components
Test example 1 inhibition experiments of different compositions on non-enzymatic glycosylation reactions
To 100mL of a phosphate buffer solution of 0.2mol/L at pH=7.4, 19.82g of glucose, 0.4024g of bovine serum albumin and 0.39g of sodium azide were added, and the mixture was uniformly mixed to obtain a reaction solution.
The compositions prepared in examples 1 to 3 and cases 1 to 11 were prepared by using distilled water as the test solutions of different concentrations, and the concentrations were 50. Mu.g/mL, 100. Mu.g/mL, 200. Mu.g/mL, 400. Mu.g/mL, 600. Mu.g/mL, 800. Mu.g/mL, and 1000. Mu.g/mL.
14 test tubes are taken, 4mL of reaction solution and 1mL of to-be-tested solution with different concentrations are sequentially added into each test tube, so that the total volume of the solutions in all the test tubes is 5mL. Measuring initial fluorescence values of all samples by adopting a fluorescence spectrophotometer, then placing all test tubes in a water bath at 37 ℃ and keeping the test tubes in a dark place for 7d, and measuring the fluorescence values of the samples in all the test tubes; the fluorescence value was determined after further storage of all tubes in a 37℃water bath protected from light for 7 d. The test conditions were: excitation wavelength is 370nm, and slit is 5nm; the emission wavelength ranges from 380 nm to 500nm, and the slits are 5nm; the light source voltage is 700V.
The inhibition results of the non-enzymatic glycosylation reaction by the different compositions are shown in the following table 2, and the compositions of examples 1-3 and cases 1-11 are tested to have the activity of inhibiting the non-enzymatic glycosylation reaction, but have different inhibition capacities on the non-enzymatic glycosylation reaction; the compositions of examples 1-3 have good inhibition rate on non-enzymatic glycosylation reaction at different concentrations, the inhibition rate is between 63.46 and 78.94 percent, the inhibition rate is obviously superior to other case compositions at the same concentration, and the composition of example 1 has the best proportioning effect, and the inhibition rate can reach 78.94 percent. In cases 1 to 3 containing only one component, however, the inhibition effect on the non-enzymatic glycosylation reaction was poor. In cases 4 to 9, the inhibition effect of the non-enzymatic glycosylation reaction by the two-component composition was slightly improved compared with cases 1 to 3, but the effect was significantly lower than that of the compositions of examples 1 to 3, and the effect was not as good as that of the compositions of examples 1 to 3 even if the two-component and single component effects were simply added. In cases 10 to 11, the effect of the composition obtained by compounding by adjusting the addition ratio of the tricholoma matsutake extract on inhibiting the non-enzymatic glycosylation reaction is better than that of cases 1 to 9, which is a step-by-step improvement, than that of the single component and the two components, but is inferior to that of the embodiments 1 to 3 of the present invention.
TABLE 2 inhibition of non-enzymatic glycosylation reactions by different compositions
In conclusion, the composition obtained by compounding the tricholoma matsutake extract, the bakuchiol and the ergothioneine has good non-enzymatic glycosylation reaction inhibition effect, good anti-aging effect, and obvious synergistic effect, and the efficacy is obviously superior to that of the single use of each component or the simple superposition of the two components.
Test example 2 protection of compositions against UVB-induced aging
The compositions prepared in examples 1 and 3 and cases 1 and 6 were used to evaluate the protective effect on UVB-induced skin damage in Kunming mice: the effect of the composition on the skin of mice was observed by skin histology and pathological section. Respectively taking the normally raised small partsThe mice (KM mice (6-8 weeks of week old) were dehaired in their back region, and irradiated with ultraviolet (UVA irradiation intensity accumulated to 148.47J/cm) 2 The UVB irradiation intensity is accumulated to 48.67J/cm 2 ) And performing drug application treatment. The experimental mice were grouped into a blank control group (C), a model control group (MC), and a composition low dose group (D), a composition high dose group (F), a composition without matsutake extract (Y), and a matsutake extract only low dose group (G).
The different compositions were dissolved in 30% ethanol aqueous solution as experimental drugs, respectively, and the concentrations of the drugs of each group were controlled to be the same. Wherein the blank control group (C) and the model control group (MC) are directly applied with 2mL of ethanol aqueous solution coated with 30%; the composition low dose group (D) was applied with 2mL of the drug solution prepared with the composition of example 1 (5% matsutake extract+0.5% bakuchiol+0.01% ergothioneine); the composition high dose group (F) was smeared with 2mL of a drug solution prepared with the composition of example 3 (10% Tricholoma matsutake extract+1% bakuchiol+0.03% ergothioneine); drug treatment group (Y) was 2ML of solution applied using case 6 composition (0.5% bakuchiol +0.01% ergothioneine); the drug treatment group (G) was a 2ML solution applied using the case 1 composition (5% Tricholoma matsutake extract). The medicine is applied 15min after each UVB irradiation. Mice were treated weekly and observed for status; the photoaging scoring criteria of the mice were optimized by the prior art in combination with experimental sample conditions, as shown in table 2, to further evaluate changes in the skin of the mice.
TABLE 2 mouse photoaging scoring criteria
| Scoring of | Characterization (wrinkles) | Scoring of | Characterization (injury) |
| 1 | Smooth skin without wrinkles | 1 | Skin smoothness |
| 2 | With fine marks | 2 | Has a small amount of scab |
| 3 | Has small amount of shallow wrinkles | 3 | Moderate scab formation |
| 4 | A large number of |
4 | Scab and erythema are severely distributed |
| 5 | Skin is thickened and wrinkles are deep | 5 | Inflammation |
Results as shown in fig. 1, in fig. 1a, it can be seen that these changes caused by UVB radiation are significantly improved in mice treated with the combination drug by observing the conditions of wrinkles, dryness, and erythema of the skin of the mice, and that the uv-irradiated model group (MC) promotes dryness, erythema, and rough wrinkles, and even significant skin loss of flesh color, compared to the healthy back skin of the normal control group (C); after the external application of the composition (D) of example 1, there was a tendency to inhibit UVB-induced large-area erythema and leather-like appearance. The effect of the composition is obviously superior to that of the groups F and Y, the repairing effect of the group G which only smears the medicine of the tricholoma matsutake extract on the photo-aging damage is superior to that of the group Y which does not contain the tricholoma matsutake extract, but the effect is still not obvious as that of the composition of the group D. It can be seen that the use of the composition of example 1 is effective in ameliorating skin damage caused by UVB. The back of the mice was evaluated in conjunction with table 2 and the results are shown in fig. 1b, which shows thickening of the skin of the back of the mice.
Furthermore, the effect of UV multiple epidermal thickening was further verified by quantitative analysis of average thickness of the epidermal tissue by HE staining. As shown in FIG. 1c, it is clear that the average density of the epidermis of group D is significantly improved compared with that of the model group, while the repair effect of group F is slightly worse than that of group D, and the repair effect of group G is more inferior, while the repair effect of group Y without Tricholoma matsutake extract is not significant. The results of evaluating the skin thickness of the mice in combination with Table 2 are shown in FIG. 1D, which shows that groups D and F significantly reduce the skin thickness of the skin of the mice.
Taken together, the results show that the compositions of examples 1 and 3 significantly reduce the effects of UVB-induced erythema, wrinkles, edema, and thickening of the epidermis on the back skin of mice, and protect against UVB-induced skin damage in mice.
Test example 3 protection of compositions against oxidative stress and inflammation
Oxidative stress and inflammation are major factors causing photodamage to the skin. Further studies were performed by enzyme-linked immunosorbent assay (enzyme-linked immunosorbent assay, ELISA) using skin tissues from mice in the blank, model, and example 1 composition treatment group (D), and vitamin E group as positive control (control treatment was performed according to the treatment method conditions of example 6) and treated skin tissues from mice, each group of skin tissues was homogenized to obtain supernatant, and IL-1 beta, IL-6, COX-2, TNF-alpha levels in the skin tissue homogenates were determined, for specific procedures, with strict reference to the kit.
The results are shown in Table 4, and show that under UVB induction, inflammatory factors IL-6 and TNF- α are significantly increased (P < 0.01) in the skin of the model group compared with the blank group, and IL-1β and COX-2 also have an ascending trend. Notably, the example 1 composition was able to significantly reduce IL-1 beta in skin (P < 0.05), IL-6 in skin to 63.55 + -42.81 pg/mL (P < 0.05), COX-2 to 3.53+ -2.22 ng/mL (P < 0.05), and TNFα to 5.95+ -3.39 pg/mL (P < 0.01) compared to the blank. Vitamin E was able to significantly reduce COX-2 and TNF- α levels (P < 0.05) compared to the model group. The compositions of example 1 showed a decrease in IL-1β, IL 6, TNFα, COX-2 compared to the vitamin E group, and were superior to the vitamin E group.
TABLE 4 influence of test substances on inflammatory factors in UVB-induced photo-aged skin of ICR mice
| Group of | IL-1β/pg/mL | IL-6/pg/mL | COX-2/ng/mL | TNF-α/pg/mL |
| Blank group | 77.79±59.57 | 82.89±48.88 | 4.94±2.23 | 9.22±7.41 |
| Model group | 120.30±109.21 | 160.63±61.79 ** | 6.05±4.61 | 31.33±0.28 ** |
| Vitamin E group | 111.20±106.47 | 100.55±70.42 | 4.63±3.52 # | 15.42±6.45 **# |
| Example 1 | 32.24±26.23 * | 63.55±42.81 # | 3.53±2.22 # | 5.95±3.39 ## |
Note that: * Indicating significant differences between groups.
The results in conclusion show that the composition of the embodiment 1 provided by the invention can obviously reduce the levels of oxidative stress and inflammatory factors IL-1 beta, IL-6, COX-2 and TNF-alpha, avoid causing skin photodamage and have a protective effect on the skin damage of mice induced by UVB radiation.
Example 5
The comparative example was the same as example 1, the only difference being that the ratio of feed to liquid in the extraction method of matsutake extract was different: extracting according to a feed liquid ratio of 1:5 to obtain the tricholoma matsutake alcohol extract.
Example 6
The comparative example was the same as example 1, the only difference being that the ratio of feed to liquid in the extraction method of matsutake extract was different: extracting according to a feed liquid ratio of 1:15 to obtain the tricholoma matsutake alcohol extract.
Example 7
This comparative example was identical to example 1, with the only difference that the extraction temperature was different in the extraction method of the tricholoma matsutake extract: extracting with water bath at 70deg.C to obtain Tricholoma matsutake ethanol extract.
Example 8
This comparative example was identical to example 1, with the only difference that the extraction temperature was different in the extraction method of the tricholoma matsutake extract: extracting with water bath at 80deg.C to obtain Tricholoma matsutake ethanol extract.
Example 9
This comparative example was set up as in example 1, with the only difference that the ethanol solution used in the extraction method of the tricholoma matsutake extract was different: extracting with 75% ethanol solution to obtain Tricholoma matsutake ethanol extract.
Example 10
This comparative example was set up as in example 1, with the only difference that the ethanol solution used in the extraction method of the tricholoma matsutake extract was different: extracting with 85% ethanol solution to obtain Tricholoma matsutake ethanol extract.
The compositions of examples 5 to 10 were used to measure the activity of the non-enzymatic glycosylation, and the anti-aging effects of comparative examples 5 to 10 were evaluated in the same manner as in test example 1; the results show that the extraction conditions of the tricholoma matsutake extracts are adjusted in examples 5-10, the inhibition effect of the prepared tricholoma matsutake extracts on non-enzymatic glycosylation reaction is lower than that of example 1, and the inhibition effect is better than that of the single-component or two-component composition described in cases 1-9 in example 4, and the tricholoma matsutake extracts also have better anti-aging effect.
The composition provided by the invention is further used for preparing skin care products or cosmetics such as face cream, emulsion, essence and the like, and the skin care products or cosmetics also have the effects of eliminating wrinkles, resisting oxidization and repairing photo-aging damage.
Example 11
The invention provides an anti-aging skin care product containing the following components in percentage by mass: 0.3wt% of the composition of example 1, 0.3wt% of ceramide, 1.0wt% of lecithins, 0.5wt% of phytosterols, 7.5wt% of polyalcohols, 0.3wt% of chelating agents, 3wt% of thickening agents, 3.5wt% of emulsifying agents, 20.0wt% of emollients, 5wt% of fatty alcohols, 3wt% of skin conditioning agents, 0.01wt% of antioxidants, 0.01wt% of preservatives, 1.0wt% of essence and 100.0wt% of deionized water, wherein the lecithins are one or more selected from lecithins, hydrogenated lecithins and hydroxylated lecithins.
Example 12
The invention provides an anti-aging skin care product-emulsion containing the embodiment 1, which contains the following components in percentage by mass: example 1 composition 1.0wt%, glycerin 30.0wt%, sorbitol stearate 4.0wt%, sucrose cocoate 3.0wt%, dioctyl carbonate 5.0wt%, paraffin 2.0wt%, citric acid 3.0wt%, vitamin C0.1wt%, sodium stearate 1.0wt%, deionized water to 100.0wt%.
Example 13
The invention provides an anti-aging skin care product-essence containing an embodiment 1, which contains the following components in percentage by mass: 5.0wt% of the composition of example 1, 40.0wt% of butanediol; deionized water to 100.0wt%.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (10)
1. A composition with anti-aging effect, which is characterized by comprising the following components: tricholoma matsutake extract, bakuchiol and ergothioneine.
2. The composition according to claim 1, wherein the mass ratio of the tricholoma matsutake extract, the bakuchiol and the ergothioneine is: (1-10): (0.1-1): (0.01-0.05).
3. The composition according to claim 2, wherein the mass ratio of the tricholoma matsutake extract, the bakuchiol and the ergothioneine is: (5-10): (0.5-1): (0.01-0.03).
4. A composition according to claim 3, wherein the mass ratio of tricholoma matsutake extract, bakuchiol and ergothioneine is: (5-7.5): (0.5-0.75): (0.01-0.02).
5. The composition according to any one of claims 1 to 4, wherein the preparation method of the tricholoma matsutake extract comprises: adding 75-85% ethanol solution according to a feed liquid ratio of 1 (5-15), extracting for 1-3 hr at 70-80deg.C under water bath heating, extracting for 2-3 times, filtering, concentrating, and diluting to obtain Tricholoma matsutake extract.
6. Use of a composition according to any one of claims 1 to 4 for the preparation of an anti-ageing, photoaging-resistant product.
7. Use of a composition according to any one of claims 1 to 4 for the preparation of a non-enzymatic glycosylation inhibitor.
8. An anti-aging and anti-photoaging product, which is characterized by comprising the composition according to any one of claims 1 to 4 and auxiliary materials.
9. The product of claim 8, wherein the adjunct comprises at least one of a humectant, an antioxidant, an emollient, and a preservative.
10. The use according to claim 6, or the product according to claim 8 or 9, characterized in that the product is a skin care product or a cosmetic product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310432643.2A CN116421482B (en) | 2023-04-20 | 2023-04-20 | Composition containing tricholoma matsutake extract with anti-aging effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310432643.2A CN116421482B (en) | 2023-04-20 | 2023-04-20 | Composition containing tricholoma matsutake extract with anti-aging effect and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116421482A true CN116421482A (en) | 2023-07-14 |
| CN116421482B CN116421482B (en) | 2023-11-21 |
Family
ID=87081285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310432643.2A Active CN116421482B (en) | 2023-04-20 | 2023-04-20 | Composition containing tricholoma matsutake extract with anti-aging effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421482B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116942544A (en) * | 2023-08-11 | 2023-10-27 | 稀物集(广州)生物科技有限公司 | Tricholoma matsutake alcohol-containing microcapsule with anti-aging effect and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111202755A (en) * | 2020-03-06 | 2020-05-29 | 无限极（中国）有限公司 | Application of tricholoma matsutake extract |
| CN113786363A (en) * | 2021-09-10 | 2021-12-14 | 陕西澳美娅生物科技有限公司 | Formula of tricholoma matsutake soothing and repairing mask and preparation method thereof |
-
2023
- 2023-04-20 CN CN202310432643.2A patent/CN116421482B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111202755A (en) * | 2020-03-06 | 2020-05-29 | 无限极（中国）有限公司 | Application of tricholoma matsutake extract |
| CN113786363A (en) * | 2021-09-10 | 2021-12-14 | 陕西澳美娅生物科技有限公司 | Formula of tricholoma matsutake soothing and repairing mask and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| "稀物集松茸双萃紧致抗皱精华液", Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=1088901947555053568&gb=G> * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116942544A (en) * | 2023-08-11 | 2023-10-27 | 稀物集(广州)生物科技有限公司 | Tricholoma matsutake alcohol-containing microcapsule with anti-aging effect and preparation method and application thereof |
| CN116942544B (en) * | 2023-08-11 | 2024-03-29 | 稀物集(广州)生物科技有限公司 | Tricholoma matsutake alcohol-containing microcapsule with anti-aging effect and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116421482B (en) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109431841B (en) | Antioxidant and anti-aging whitening essence and preparation method thereof | |
| CN109893464A (en) | It is a kind of to block the whitening spot-removing skin care item and preparation method thereof for inhibiting reduction melanin | |
| CN111450010A (en) | Composition with anti-aging effect and application thereof in cosmetics | |
| EP2670382B1 (en) | Cosmetic use | |
| CN116421482B (en) | Composition containing tricholoma matsutake extract with anti-aging effect and application thereof | |
| KR20120027172A (en) | Composition for treatment and/or prevention of dermatopathy | |
| US9381145B2 (en) | Botanical extracts from oil palm vegetation liquor for cosmeceutical applications | |
| WO2006134583A1 (en) | Cosmetic compositions containing lingonberry (vaccinium vitis idea) extracts | |
| CN113425639B (en) | Antioxidant composition, application thereof and product | |
| CN113730321B (en) | Anti-wrinkle firming composition and application thereof in cosmetics | |
| Saritani et al. | Clitoria ternatea L. extract cream 5% inhibits the increase of MMP-1 levels and decrease of collagen amount in Wistar rats (Rattus norvegicus) dermic skin exposed to ultraviolet B | |
| WO2013050697A2 (en) | Use of glucans obtained from prunus persica as an anti-aging cosmetic agent | |
| CN114344202B (en) | Anti-aging composition, skin care product and cosmetic | |
| CH700735B1 (en) | Biologically active complex, useful e.g. as a cosmetic anti-aging composition, comprises a combination of amino acids, a soy protein hydrolyzate, teprenone and fine Myrtus communis plant extract | |
| CN110840785B (en) | Cosmetic composition for improving skin aging or skin wrinkles | |
| KR101086227B1 (en) | Cosmetic Composition Comprising the extract of Lloydia triflora Bak as Active Ingredient | |
| KR101762111B1 (en) | Cosmetic composition comprising Malva verticillata Seed extract for prevention of skin aging or anti-wrinkles | |
| Kim et al. | Protective effects of red orange (Citrus sinensis [L.] Osbeck [Rutaceae]) extract against UVA-B radiation-induced photoaging in Skh: HR-2 mice | |
| CN113633599A (en) | Skin foundation essence containing dendrobium officinale extract and preparation method thereof | |
| CN112402342A (en) | Anti-aging cosmetic additive and preparation method thereof | |
| Yatsuhashi et al. | Effects of oral supplementation with paprika xanthophylls on human skin moisture | |
| KR102161387B1 (en) | A composition comprising lutein for improving skin condition and a fuctional food comprising the composition | |
| US20230140298A1 (en) | Topical composition comprising retinol and pdrn and use of same | |
| Parwata et al. | Administration of 15% Red Beet (Beta Vulgaris) Extract Cream Inhibited The Increased Expression of Mmp-1 and The Decreased Amount of Collagen in Wistar Strained Rat (Rattus Norvegicus) Exposed to Ultra Violet-B Light | |
| CN116211775A (en) | Anti-aging skin care product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |